Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
- PMID: 36567161
- PMCID: PMC9750888
- DOI: 10.1016/j.resinv.2022.11.005
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
Abstract
Background: Several reports have revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection tends to have more severe outcomes in cancer patients. Although vaccination reduces the risk of severe disease, data on antibody titers achieved by vaccination is scarce in cancer patients.
Methods: We collected 79 blood samples (69 lung cancer patients and 10 control individuals) and conducted an anti-SARS-CoV-2 antibody assay to compare the antibody titer achieved with current treatment. Sixty-eight patients (86%) received the BNT162 mRNA vaccine and 11 (14%) received the mRNA-1273 vaccine. They were categorized according to the current treatment: control individuals without cancer (cohort A), lung cancer patients who were treated with cytotoxic chemotherapy (cohort B), immunotherapy (cohort C), combination of cytotoxic chemotherapy and immunotherapy (cohort D), tyrosine kinase inhibitors (cohort E), and radiation therapy (cohort F).
Results: Among 69 lung cancer patients (cohort B-F), 57 (83%) had adenocarcinoma, and 66 (96%) had advanced-stage cancer. In the anti-SARS-CoV-2 antibody assay, the antibody titer was significantly lower in lung cancer patients than in control individuals (p = 0.01). The median antibody titers were 161 AU/ml in control individuals and 59.9 AU/ml in lung cancer patients.
Conclusions: Antibody titers after the second vaccination were lower in cancer patients than those in healthy individuals. Our findings provide essential information for understanding the benefits and necessity of additional vaccination to prevent SARS-CoV-2 infection in lung cancer patients.
Keywords: Anti-SARS-CoV-2 antibody assay; BNT162 mRNA vaccine; Lung cancer; SARS-CoV-2; mRNA-1273 vaccine.
Copyright © 2022 [The Author/The Authors]. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest All authors have no conflict of interest to declare.
Figures
Similar articles
-
SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.Clin Exp Nephrol. 2022 Oct;26(10):988-996. doi: 10.1007/s10157-022-02243-8. Epub 2022 Jun 25. Clin Exp Nephrol. 2022. PMID: 35751753 Free PMC article.
-
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.JAMA Oncol. 2022 May 1;8(5):748-754. doi: 10.1001/jamaoncol.2022.0001. JAMA Oncol. 2022. PMID: 35266953 Free PMC article.
-
Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.Front Immunol. 2022 Jul 5;13:908108. doi: 10.3389/fimmu.2022.908108. eCollection 2022. Front Immunol. 2022. PMID: 35911701 Free PMC article.
-
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.Vaccine. 2022 Sep 9;40(38):5631-5640. doi: 10.1016/j.vaccine.2022.08.018. Epub 2022 Aug 15. Vaccine. 2022. PMID: 36028457 Free PMC article.
-
Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.Thorac Cancer. 2022 Feb;13(3):453-459. doi: 10.1111/1759-7714.14281. Epub 2021 Dec 28. Thorac Cancer. 2022. PMID: 34964270 Free PMC article.
References
-
- WHO Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int/
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous